NIH Grants $2 million to Symbiotix to Advance Treatment for IBD

NIH Grants $2 million to Symbiotix to Advance Treatment for IBD
The National Institutes of Health’s (NIH) National Institute of Diabetes and Digestive and Kidney Diseases recently granted Symbiotix Biotherapies $2 million to support research and of development of Polysaccharide A (PSA), the first potentially therapeutic molecule to emerge from the human microbiome and a possible new therapeutic avenue for diseases such as inflammatory bowel disease

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *